<DOC>
	<DOCNO>NCT01206881</DOCNO>
	<brief_summary>The purpose study determine efficacy neoadjuvant treatment pegylated liposomal doxorubicin ( Caelyx ) cyclophosphamide +/- trastuzumab follow docetaxel patient locally advance , inflammatory breast cancer primary tumor &gt; 5 cm .</brief_summary>
	<brief_title>Neoadjuvant Pegylated Liposomal Doxorubicin Cyclophosphamide +/- Trastuzumab Followed Docetaxel Breast Cancer</brief_title>
	<detailed_description>Patients locally advance inflammatory breast cancer bad prognosis . Several study show patient receive pathological complete response best prognosis . Neoadjuvant chemotherapy include anthracyclines taxanes become establish standard option multidisciplinary management group patient . In HER2 positive patient , chemotherapy combination trastuzumab therapeutically attractive . Recent study also demonstrate evaluation PET-CT scan use stratify treatment monitor early response neoadjuvant therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>pathologically prove breast cancer inflammatory , locally advanced breast cancer tumor &gt; 5 cm ECOG performance status &lt; 2 LVEF &gt; 50 % measure MUGA ( HER2 positive patient ) adequate bone marrow , liver renal function write informed consent must obtain another malignancy within 5 year prior study entry concurrent treatment investigational agent disease condition contraindicate participation study pregnant lactating female</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>liposomal doxorubicin</keyword>
	<keyword>PET scan</keyword>
</DOC>